MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Home・Aandelen Lijst・Veracyte Inc

Veracyte Inc

Gesloten

SectorGezondheidszorg

31.23 -4.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.87

Max

32.59

Belangrijke statistieken
By Trading Economics
Inkomsten	30M 49M
Verkoop	8.8M 141M
K/W Sectorgemiddelde	39.415 66.418
Winstmarge	34.967
Werknemers	755
EBITDA	22M 46M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+32.38% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-258M 2.6B
Vorige openingsprijs	35.49
Vorige sluitingsprijs	31.23

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

30.5 / 31.38 Steun & Weerstand

Veracyte Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 apr 2026, 18:16 UTC

Belangrijke Nieuwsgebeurtenissen

Bank of Mexico Cautious After Interest-Rate Cut, Minutes Show

9 apr 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Marktinformatie

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Marktinformatie

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Marktinformatie

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Belangrijke Nieuwsgebeurtenissen

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Winsten

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Winsten

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisities, Fusies, Overnames

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Belangrijke Nieuwsgebeurtenissen

How Digital Currencies Have Helped Iran -- WSJ

9 apr 2026, 19:25 UTC

Marktinformatie

Crude Futures End Volatile Session Higher -- Market Talk

9 apr 2026, 19:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 apr 2026, 19:16 UTC

Marktinformatie

Livestock Mixed After USDA Cuts Production Outlook -- Market Talk

9 apr 2026, 18:55 UTC

Marktinformatie

Global Energy Roundup: Market Talk

9 apr 2026, 18:55 UTC

Marktinformatie

U.S. Natural Gas Futures Fall On Weather, Storage Data -- Market Talk

9 apr 2026, 18:50 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 apr 2026, 18:44 UTC

Marktinformatie

Barrick's Former CEO Paid Severance Package of More Than $21 Million -- Market Talk

9 apr 2026, 18:20 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Pulls Back As Israel to Negotiate With Lebanon -- Market Talk

Peer Vergelijking

Prijswijziging

Veracyte Inc Prognose

Koersdoel

By TipRanks

32.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 43.25 USD 32.38%

Hoogste 48 USD

Laagste 37 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Veracyte Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Veracyte Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

30.5 / 31.38Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.